Vyome Holdings Inc (HIND)

$5.09 +0.08 (1.60%)
Market Cap 27.97M
Revenue (ttm) 8.01M
Net Income (ttm) -7.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89.01%
Debt to Equity Ratio 0.00
Volume 14,200
Avg Vol 73,356
Day's Range N/A - N/A
Shares Out 5.64M
Stochastic %K 66%
Beta 1.21
Analysts Strong Sell
Price Target $15.00

Company Profile

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 973-832-8147
Address:
Harvard Square, One Mifflin Place Suite 400, Cambridge, United States
saudq1978
saudq1978 Dec. 3 at 11:09 PM
$HIND $SPY 55 basis points. NOT AGAIN MAN!
0 · Reply
MarketEyeX2
MarketEyeX2 Nov. 28 at 5:41 PM
$HIND Shorts tried, got nothing - N/X/X/T refused to break structure, now the path of least resistance is UP 🔥
0 · Reply
VyomeInc1
VyomeInc1 Nov. 25 at 8:36 PM
$HIND Vyome Holdings is pleased to share that it has appointed Dr. Aditya Bardia as Senior Medical Advisor for our VT1953 program in malignant fungating wounds. His deep experience in advancing oncology therapeutics and pivotal trials strengthens our mission. VT1953 continues to advance with positive interim Phase 2 Investigator Initiated Trial results and a potential path toward orphan drug designation in this highly underserved condition. Our commitment remains clear: disciplined execution and significant impact for patients.
0 · Reply
Crystalgator
Crystalgator Nov. 20 at 5:09 PM
$HIND is this company dead
0 · Reply
Magnificent77
Magnificent77 Nov. 18 at 10:00 PM
$HIND Tech down, lets shift into biotech we gunna boom
0 · Reply
thesouradeep
thesouradeep Nov. 12 at 5:22 PM
$HIND hit their twitter. Krishna K Gupta. Vikram Nelabhotla and some Dr. confident. Like they post something and 2 people likes the post hahahhaha. Fucking scammers
0 · Reply
Shane393
Shane393 Nov. 11 at 9:56 PM
$HIND In just 12.5 short weeks vyome has cut the value of reshape into 1/3. They promised topline data for 1953 mid October and it never happened. They have no earnings and pivots point to a price of $3.90. With there topline data missing that they boasted about and no earnings its primed to drop another 30- 50 percent. Short away from here and any pop into earnings.
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 6:02 PM
$CRIS $HIND REQUIRE YOUR SERVICES SOON ISH
0 · Reply
Shane393
Shane393 Nov. 5 at 9:39 PM
$HIND Reshape 2.0
0 · Reply
movam
movam Nov. 3 at 6:47 PM
$HIND $10.
0 · Reply
Latest News on HIND
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Nov 25, 2025, 7:00 AM EST - 9 days ago

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Nov 18, 2025, 7:00 AM EST - 16 days ago

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation

Nov 5, 2025, 10:13 AM EST - 4 weeks ago

Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation

RSLS

Vyome Holdings Announces Results of Annual Shareholder Meeting

Nov 4, 2025, 9:04 AM EST - 4 weeks ago

Vyome Holdings Announces Results of Annual Shareholder Meeting

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Sep 29, 2025, 7:00 AM EDT - 2 months ago

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Sep 17, 2025, 7:00 AM EDT - 2 months ago

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Sep 9, 2025, 8:30 AM EDT - 3 months ago

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Sep 4, 2025, 8:30 AM EDT - 3 months ago

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

Aug 21, 2025, 7:00 AM EDT - 3 months ago

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Aug 18, 2025, 8:30 AM EDT - 3 months ago

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Aug 15, 2025, 8:00 AM EDT - 3 months ago

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

Aug 14, 2025, 7:18 PM EDT - 4 months ago

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

RSLS

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

Aug 13, 2025, 11:50 AM EDT - 4 months ago

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

RSLS

Vyome Announces New Board of Directors with Deep MIT and AI Ties

Aug 12, 2025, 9:48 AM EDT - 4 months ago

Vyome Announces New Board of Directors with Deep MIT and AI Ties

RSLS

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

Aug 7, 2025, 5:01 PM EDT - 4 months ago

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

RSLS

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Jul 24, 2025, 4:39 PM EDT - 4 months ago

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

RSLS

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

Jul 22, 2025, 8:31 AM EDT - 4 months ago

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

RSLS

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

Jul 21, 2025, 2:10 PM EDT - 4 months ago

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

RSLS

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

Jul 1, 2025, 8:31 AM EDT - 5 months ago

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

RSLS

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

Jun 27, 2025, 9:01 AM EDT - 5 months ago

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

RSLS

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Jun 26, 2025, 8:31 AM EDT - 5 months ago

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

RSLS

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

Jun 25, 2025, 8:31 AM EDT - 5 months ago

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

Jun 12, 2025, 8:25 AM EDT - 6 months ago

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

RSLS

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

Jun 9, 2025, 9:00 AM EDT - 6 months ago

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

RSLS

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

Jun 3, 2025, 8:31 AM EDT - 6 months ago

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

RSLS

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

May 21, 2025, 8:31 AM EDT - 7 months ago

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

RSLS

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

May 12, 2025, 8:32 AM EDT - 7 months ago

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ORLA RSLS

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

May 7, 2025, 8:31 AM EDT - 7 months ago

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

RSLS

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

May 2, 2025, 8:31 AM EDT - 7 months ago

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

RSLS

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

Apr 28, 2025, 8:31 AM EDT - 7 months ago

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

RSLS

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Apr 21, 2025, 8:31 AM EDT - 8 months ago

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)

Apr 10, 2025, 5:54 PM EDT - 8 months ago

ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)

RSLS

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

Apr 9, 2025, 4:05 PM EDT - 8 months ago

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

RSLS

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Apr 7, 2025, 4:05 PM EDT - 8 months ago

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

RSLS

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

Mar 21, 2025, 11:35 AM EDT - 9 months ago

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

RSLS

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Mar 10, 2025, 8:31 AM EDT - 9 months ago

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

Feb 25, 2025, 8:31 AM EST - 10 months ago

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

RSLS

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

Feb 15, 2025, 11:17 PM EST - 10 months ago

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

RSLS

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

Feb 3, 2025, 8:31 AM EST - 10 months ago

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Jan 13, 2025, 8:31 AM EST - 11 months ago

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

RSLS

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:43 PM EST - 1 year ago

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

RSLS

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Nov 12, 2024, 4:05 PM EST - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

RSLS

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

Nov 12, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

RSLS

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

Nov 11, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

RSLS

ReShape Lifesciences Announces 1-for-58 Reverse Stock Split

Sep 19, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences Announces 1-for-58 Reverse Stock Split

RSLS

ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 8:42 PM EDT - 1 year ago

ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript

RSLS

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Aug 13, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

RSLS

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders

Jul 19, 2024, 8:05 AM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders

CHUY RSLS

Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”

Jul 9, 2024, 12:13 PM EDT - 1 year ago

Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”

RSLS

saudq1978
saudq1978 Dec. 3 at 11:09 PM
$HIND $SPY 55 basis points. NOT AGAIN MAN!
0 · Reply
MarketEyeX2
MarketEyeX2 Nov. 28 at 5:41 PM
$HIND Shorts tried, got nothing - N/X/X/T refused to break structure, now the path of least resistance is UP 🔥
0 · Reply
VyomeInc1
VyomeInc1 Nov. 25 at 8:36 PM
$HIND Vyome Holdings is pleased to share that it has appointed Dr. Aditya Bardia as Senior Medical Advisor for our VT1953 program in malignant fungating wounds. His deep experience in advancing oncology therapeutics and pivotal trials strengthens our mission. VT1953 continues to advance with positive interim Phase 2 Investigator Initiated Trial results and a potential path toward orphan drug designation in this highly underserved condition. Our commitment remains clear: disciplined execution and significant impact for patients.
0 · Reply
Crystalgator
Crystalgator Nov. 20 at 5:09 PM
$HIND is this company dead
0 · Reply
Magnificent77
Magnificent77 Nov. 18 at 10:00 PM
$HIND Tech down, lets shift into biotech we gunna boom
0 · Reply
thesouradeep
thesouradeep Nov. 12 at 5:22 PM
$HIND hit their twitter. Krishna K Gupta. Vikram Nelabhotla and some Dr. confident. Like they post something and 2 people likes the post hahahhaha. Fucking scammers
0 · Reply
Shane393
Shane393 Nov. 11 at 9:56 PM
$HIND In just 12.5 short weeks vyome has cut the value of reshape into 1/3. They promised topline data for 1953 mid October and it never happened. They have no earnings and pivots point to a price of $3.90. With there topline data missing that they boasted about and no earnings its primed to drop another 30- 50 percent. Short away from here and any pop into earnings.
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 6:02 PM
$CRIS $HIND REQUIRE YOUR SERVICES SOON ISH
0 · Reply
Shane393
Shane393 Nov. 5 at 9:39 PM
$HIND Reshape 2.0
0 · Reply
movam
movam Nov. 3 at 6:47 PM
$HIND $10.
0 · Reply
resistancebreakers
resistancebreakers Nov. 3 at 5:17 PM
$HIND on the move 🪖🫡☝️
0 · Reply
hockeyfan530
hockeyfan530 Nov. 3 at 4:42 PM
$HIND would love to see this with some volume
0 · Reply
movam
movam Nov. 3 at 4:14 PM
$HIND see you at $10
0 · Reply
ReformedTraders
ReformedTraders Nov. 1 at 7:29 PM
$LBGJ $OP.X $HIND $CGTX
2 · Reply
movam
movam Oct. 31 at 12:01 PM
$HIND $10
0 · Reply
movam
movam Oct. 26 at 3:49 PM
$HIND $10.
0 · Reply
muriokurt
muriokurt Oct. 20 at 3:02 PM
$HIND @KKG2020 Any word on $LICH bro? Been a long "month" since the PR...
0 · Reply
drwaz
drwaz Oct. 15 at 12:37 PM
$HIND 👀
0 · Reply
saudq1978
saudq1978 Oct. 14 at 5:12 AM
$HIND $SPY wow
0 · Reply
saudq1978
saudq1978 Oct. 14 at 4:29 AM
$CVNA $HIND hmm
1 · Reply
saudq1978
saudq1978 Oct. 14 at 4:28 AM
$HIND $SPY
0 · Reply
saudq1978
saudq1978 Oct. 14 at 4:27 AM
$HIND
0 · Reply